Pregnant woman and wife taking selfie

What The Maternal Fetal Screen | T1SM Screens For

Chromosomal Abnormalities

The chromosome abnormalities screened for in this test including:

Early Onset Preeclampsia (EOPE)

Preeclampsia is a serious disease related to high blood pressure. It can happen to any pregnant woman during the second half of her pregnancy. When it results in the delivery of your baby  before 34 weeks’ gestation, it is called “early onset preeclampsia,” and is often more dangerous to you and your baby.

NTD also offers stand-alone preeclampsia screening that does not include a risk assessment for Down syndrome, Trisomy 18 (Edwards Syndrome), or Trisomy 13 (Patau Syndrome).

Learn more about our Preeclampsia Screen | T1SM

Y Chromosome Assessment

Y chromosome assessment is an option available to patients who are pregnant with one baby that will assess the presence or absence of the Y chromosome. The presence of a Y chromosome is predictive of a male baby, while the absence of the Y chromosome typically means the baby is female. The result of this added evaluation will further refine your risk analyses for Down syndrome, Trisomy 18, Trisomy 13 and early onset preeclampsia.

Other Obstetric Complications

By analyzing the biological markers in mom’s blood, Maternal Fetal Screen | T1SM casts a wide net and also offers insight into other maternal and fetal issues, such as aneuploidy, preeclampsia, low birth weight, fetal loss, and stillbirth.

 

Biochemical Ultrasound Screening chart

*Information provided if second trimester screening is included.

How It Works

  • Droplet icon

    Biochemical:

    A maternal blood sample is analyzed for five biochemical markers-free Beta hCG, PAPP-A (pregnancy-associated plasma protein-A), AFP (alpha fetoprotein), PIGF (placental growth factor) and dimeric inhibin A (DIA).

  • Ultrasound icon

    Biophysical:

    An ultrasound examination confirms how far along you are in your pregnancy and measures the nuchal translucency (NT), or the fluid accumulation behind the baby’s neck. When a Fetal Nasal Bone Assessment is added to the protocol, the detection rate for Down syndrome increases. If early onset preeclampsia screening is recommended to maximize the detection efficiency, a further ultrasound will evaluate uterine artery doppler pulsatility index, and your blood pressure will be taken.

Uterine Artery Doppler Pulsatility Index

Normal First Trimester Uterine Artery Doppler (UtAD)

First Trimester Uterine Artery Doppler normal

Abnormal First Trimester Uterine Artery Doppler (UtAD)

First Trimester Uterine Artery Doppler abnormal

The Advantages of Free Beta hCG:

NTD Eurofins is the only laboratory that utilizes free beta hCG in their prenatal screening protocol. The use of free beta hCG in screening for Down syndrome and other chromosomal abnormalities has been demonstrated to be more effective than intact or total hCG. Intact/total hCG, while an effective second trimester marker, is far less effective during the first trimester.

Detection Rates

Down Syndrome

Detection Rate
False Positive

Trisomy 18/13

Detection Rate
False Positive

EOPE

Detection Rate
False Positive

Y Chromosome Assessment

Detection Rate
False Positive

Test Results

Turn around time: Results can be expected 2-5 days from the time the sample is received at the laboratory. Turn around time is 3-6 days when adding additional EOPE and Y Chromosome Assessment test options.

Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.

Learn More
Trust

Our Goal is to Educate and Empower

Know your choices, understand your options, and talk you your healthcare provider about the best prenatal screening program for you.

Learn more

The detection of Y chromosome assay has been validated for a minimum presence of 4% fetal fraction in the cell free DNA extraction. Therefore failure to detect Y chromosome signal may occur where there is less than 4% fetal fraction. It has been noted that with increased maternal weight, the likelihood of less than 4% fetal fraction increases. For example, at 11-13 weeks gestation over 11% of the mothers that weigh over 240 lbs have fetal fraction <4% (Ashoor G, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013 Jan;41(1):26-32. PMID: 23108725).